Adherence to somatotropin treatment administered with an electronic device

• Published in: Endocrinología, diabetes y nutrición. diabetes y nutrición., 2018-06, Vol.65 (6), p.314-318
• Main Authors: Arrabal Vela, María Auxiliadora, García Gijón, Carlota Prado, Pascual Martin, María, Benet Giménez, Isabel, Áreas Del Águila, Vera, Muñoz-Rodríguez, José Ramón, Palomo Atance, Enrique
• Format: Article
• Language: eng ; spa
• ISSN: 2530-0180
• DOI: 10.1016/j.endinu.2018.02.003

INTRODUCTIONAdherence to somatotropin treatment is associated with increased growth velocity and improved adult height. The purpose of this study is to determine the adherence of patients undergoing treatment with an electronic device and its relationship with different variables (age, gender, duration of treatment, diagnosis, height, and growth rate). MATERIAL AND METHODSDescriptive, longitudinal and retrospective study of children less than 14 years of age undergoing treatment with somatotropin administered with the Easypod® electronic device in the Paediatric Endocrinology Outpatient Clinic of the General University Hospital of Ciudad Real, Spain. Adherence was monitored for 12 months and was defined according to the equation: (days administered at the prescribed dose / prescribed days)×100. The data analysis was performed using SPSS software. RESULTSData were collected from 30 patients, with a predominance of males (57%), a mean age of 6.09 years, with 51% of children less than 5 years old. The most common reasons for the treatment were: small for gestational age (55%) and growth hormone deficiency (38%). The mean duration of treatment was 4.3 years (3.6-5). A mean adherence of 92.3% (87.7-96.9) was observed, and there was a significant correlation with age (Pearson R = -0.384, P=.03), and duration of treatment (Pearson R = -0.537; P=.003). CONCLUSIONSThe adherence in our patients with electronic device is high (92.3%), and is inversely associated with age and duration. The use of electronic devices allows monitoring of therapeutic compliance, which affects the optimisation of treatment.